Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)

Editor-in-Chief

ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

Recombinant Protein Based Therapeutics for IPF

Author(s): Joseph M. Parker, Michael S. Kramer and Lynne A. Murray

Volume 12, Issue 2, 2013

Page: [109 - 123] Pages: 15

DOI: 10.2174/1871528111312020005

Price: $65

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible, and usually fatal interstitial lung disease of unknown cause [1, 2]. The aetiology of IPF is unknown, although identified risk factors for IPF include cigarette smoking, environmental exposures, microbial agents, age, male gender and gastroesophageal reflux disease (GERD). Genetic factors may also play a role in the aetiology of IPF as familial cases of IPF are described in approximately 5% of patients with IPF [2]. Nothing has shown significant anti-fibrotic activity in IPF patients and due to this high unmet medical need, numerous therapeutics are currently under clinical investigation. In this review, we shall focus on recombinant protein based approaches for the treatment of IPF, with a particular focus on pathophysiology of lung fibrosis using the bleomycin mouse model.

Keywords: Bleomycin, epithelium, fibroblast, lung fibrosis, macrophage.

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy